HP Ingredients Nets ParActin Patent

BRADENTON, Fla.HP Ingredients reported its proprietary compound ParActin® has garnered a U.S. Patent (#8,084,495 B2) for its extraction of labdane diterpenes from the herb Andrographis paniculata, which are useful in the treatment of autoimmune diseases and Alzheimer Disease by activation for PPAR-gamma receptors. Peroxisome Proliferator Activated Receptor gamma (PPARy) is the key regulator of the immune and inflammatory response.

"This patent validates the extraordinary research supporting viable use of ParActin® in a variety of health issues that necessitate targeted support without other compromising effects such as those experienced typically from more commonly prescribed  auto-immune disease drugs and NSAIDs," said  Annie Eng, founder and CEO of HP Ingredients. "ParActin's principle extracted components have been shown to be the first natural PPARy agonist which exerts desirable protective effects in both autoimmunity and Alzheimer's cases." She noted the patent may give the company's brand marketer clients a distinct competitive edge in the brain health and joint support supplement market sectors.

On ParActin's immune mechanism, Juan Hancke, MD, the patent inventor, explained, "The present invention is able to diminish the autoimmune  response (which characterizes autoimmune diseases and allergies), alleviating the symptoms  and the course of  these  diseases, while maintaining 'immunological tolerance,' or a healthy absence of an autoimmune response. We believe that our composition inhibits the synthesis and expression of interferon gamma and interleukin-2, stimulates the PPARy receptor and inhibits the NF kappaB factor. Consequently, we believe these therapeutic compounds in ParActin® selectively reduce over-expression of cytokines, which over-expression is often involved in the pathogenesis of auto-immune diseases."

On Alzheimer's he noted PPARy agonists were shown to inhibit the beta-amyloid-stimulated expression of the genes for inflammatory compounds such as interleukin-6 and tumor necrosis factor- (TNFa) and the expression of COX-2. He explained there previously were no antecedents of PPARy agonist compounds isolated from medicinal plants until ParActin. "This new composition is able to reduce the pro-inflammatory cytokines production that are increased in autoimmune and neurodegenerative diseases," he explained. "Additionally, the composition of the present invention has low toxicity, and does not exhibit any harmful side effects."